Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Lebanon National Health Strategy-Vision 2030



Lebanon National Health Strategy – Vision 2030- Two Year Review
Lebanon National Health Strategy – Vision 2030- One Year Review

Introduction

In January 2023, the Ministry of Public Health (MoPH) launched its National Health Strategy: Vision 2030. Vision 2030 set out the framework for a sustained and modernized recovery of the health sector and intended to address the challenges of leading a burned-out health system. Through this strategy, and under the leadership of the MoPH, the different partners of the health sector joined efforts to respond to the escalating unmet health needs and participate in building a stronger, more resilient health system.

Over the past year, the National Health Strategy has made significant strides in enhancing the overall well-being of the population. The multifaceted approach has addressed key issues such as human resources shortage, challenged healthcare accessibility, and the massive gaps in health financing. Despite the multiple predicaments in the country, including the ongoing war and hostilities; the economic collapse and financial meltdown; the extended refugee crisis with its associated increased demand for scarce health resources; and disease outbreaks such as cholera; the health sector remained steady, and determined in achieving progress across the objectives outlined in the National Health Strategy. The National Health Strategy’s commitment to fostering advanced governance and financing mechanisms, investing in essential public health functions, strengthening primary healthcare, capacitating human resources, and embracing digital health technologies is expected to result in an advanced, more equitable, more inclusive, and more sustainable healthcare delivery.(Read More...)
 
Lebanon National Health Strategy: Vision 2030
 
Executive Summary

Lebanon is passing through one of the most severe and complex crises in its recent history, caused by the interplay of political turbulence, socioeconomic meltdown, and the lingering COVID-19 pandemic. Regionally, conflict and instability continue to result in the influx of refugees, which constitute now around one third of the Lebanese population.

The intertwined crises Lebanon has been suffering from unmasked the effects of pre-existing health system inefficiencies, including the predominance of tertiary care over preventive and primary care; a weakened public health sector; a pluralistic financing system; and a supply-induced demand with unsustainable and unrealistic expectations. The synergistic effects of these crises amplified the malfunctioning of a disrupted health system, rendering a system notorious for its resilience at the verge of a breakdown. As a result, the ability to respond to the increased needs of a growing population was deterred. Equitable access to care was exceptionally difficult for people with vulnerabilities. Worsening in health outcomes was noted at many fronts: life expectancy, maternal mortality, under 5 mortality, and childhood vaccination. Previously forgotten diseases such as diphtheria, tetanus, and most recently cholera re-emerged, and the health gains of previous years have started to fade away.

The multifaceted crisis has also severely impacted access to and utilization of healthcare services. The percentage of households with difficulty accessing health care rose from 25% to 36% within around 4 months during the year 2020. Hospitalizations, particularly for surgeries, diminished by 30% in 2021, and the average monthly hospitalization days decreased by 25%. The cost of treatments, medical consultations, or transportation to health facilities have become prohibitive to many, resulting in delayed presentation of patients for medical attention, who at many times presented with decompensated or non-salvageable conditions. Duly, challenged access to specialized healthcare was coupled with an exponential increased demand on the services provided by the Primary Health Care Network. With crisis, an opportunity has emerged for repositioning primary health care as a gateway for affordable, quality promotive, preventive, and primary health services, and for moving closer towards achieving Universal Health Coverage.

The recent drain of human resources particularly those with high competencies and specialization has become an increasing concern, with more than 20% of nurses and around 40% of doctors having already left the country. Additionally, the layoffs, salary cuts and closures of pharmacies and the reduced activities of hospitals which accompanied the economic crisis, deleteriously affected the healthcare workforce. This shortage in qualified human resources endangered the quality and availability of health care services.

The pharmaceutical sector was also hit hard by the crisis. In 2020, the government’s policy of relying on external sources for medications and medical supplies, coupled the economic crisis, led to drops in imports, resulting in severe market shortages. This has paved the way to hoarding, smuggling, black market practices, and the entry of illegal, low-quality drugs and supplies into the country.(Read More...)


ِAnnexes:
    5
    ...
ATC Name B/G Ingredients Dosage Form Price
A03A SPASMOBROM B Pipethanate Ethobromide - 20mg 20mg Tablet, coated 705,517 L.L
A03AA04 DUSPATALIN RETARD B Mebeverine HCl - 200mg 200mg Capsule 861,466 L.L
A03AA04 SPASMINE (Mebeverine HCl 200mg SR) G Mebeverine HCl - 200mg 200mg Capsule, slow release 712,876 L.L
A03AA04 BEVACOL 135 G Mebeverine HCl - 135mg 135mg Tablet, film coated 532,162 L.L
A03AB02 GLYCOPYRROLATE B Glycopyronium Bromide - 0.2mg/ml 0.2mg/ml Injectable solution 7,238,185 L.L
A03AB06 SPASMOMEN B Otilonium bromide - 40mg 40mg Tablet, film coated 438,093 L.L
A03AB06 NOSPAZM G Otilonium bromide - 40mg 40mg Tablet, film coated 282,207 L.L
A03AX COLPERMIN B Pepermint oil - 187mg 187mg Capsule, delayed release 632,950 L.L
A03AX HEPABYL G Sorbitol - 2.5g/5ml, Diisopromine - 0.02g/5ml Liquid 238,052 L.L
A03AX SPASMO-DIGESTIN B Simethicone - 30mg, Dicyclomine HCl - 5mg, Sodium dihydrocholate - 10mg, Sanzyme 3500 - 36mg, Papain - 100mg Tablet, enteric coated 260,705 L.L
A03AX12 SPASFON B Phloroglucinol hydrate - 80mg, Trimethylphloroglucinol - 80mg Tablet, coated 278,175 L.L
A03AX12 PHLOROGLUCINOL/TRIMETHYLPHLOROGLUCINOL ARROW G Phloroglucinol - 40mg/4ml, Trimethylphloroglucinol - 0.04mg/4ml Injectable solution 940,690 L.L
A03AX13 OVOL B Simethicone - 40mg/ml 40mg/ml Drops 233,829 L.L
A03AX13 SIMETHICONE G Dimethicone - 2g/100ml 2g/100ml Emulsion 212,327 L.L
A03AX13 MOSAR PLUS B Mosapride citrate - 5mg, Simethicone - 200mg Tablet, coated 865,435 L.L
A03AX13 OVOL FOR GAZ B Simethicone - 180mg 180mg Capsule, liquid gel 241,892 L.L
A03AX58 METEOSPASMYL B Alverine citrate - 60mg, Simethicone - 300mg Capsule 481,096 L.L
A03BA01 ATROPINE G Atropine sulfate - 1mg/ml 1mg/ml Injectable solution 702,149 L.L
A03BA01 ATROPINE SULFATE RENAUDIN G Atropine sulfate - 1mg/ml 0.1% Injectable solution 397,777 L.L
A03BA01 ATROPINE I.V. 0.25 MG. G Atropine - 0.25mg/ml 0.25mg/ml Injectable solution 2,412,129 L.L
A03BA01 ATROPINE G Atropine sulfate - 0.5mg/ml 0.5mg/ml Injectable solution 680,315 L.L
A03BA01 ATROPINE SULFATE RENAUDIN G Atropine sulfate - 0.5mg/ml 0.5mg Injectable solution 385,683 L.L
A03BA01 ATROPINE SULFATEAGUETTANT G Atropine - 0.1mg/ml 0.1mg/ml Injectable solution 7,805,376 L.L
A03BB01 BUSCOPAN B Butylscopolamine bromide - 10mg 10mg Tablet, sugar coated 692,079 L.L
A03BB01 BUSCOPAN B Butylscopolamine bromide - 10mg 10mg Tablet, sugar coated 291,614 L.L
A03BB01 SCOPINAL G Butylscopolamine bromide - 10mg 10mg Tablet, film coated 162,605 L.L
A03BB01 SCOPINAL G Butylscopolamine bromide - 5mg/5ml 5mg/5ml Syrup 210,983 L.L
A03BB01 ANTIPAN G Hyoscine N butylbromide - 20mg/ml Injectable solution 355,798 L.L
A03BB01 ANTIPAN G Hyoscine N butylbromide - 20mg/ml Injectable solution 2,557,140 L.L
A03BB01 SCOBUREN G Butylscopolamine bromide - 20mg/ml 20mg/ml Injectable solution 370,901 L.L
    5
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025